                                                                                  May 2  2006 Contact                                                                                                                                                                                                                                            Lieberman Calls for Incentives for Research on Disease Treatment                                                                                                                                                                                                                                                                                                                                                      Senator joins colleague in introducing Neglected Diseases Act                                                                                                                                                                                                                                                                                                                                                          WASHINGTON     U S  Senators Joe Lieberman  D CT  and Sam Brownback  R KS  today introduced the Elimination of Neglected Diseases Act of 2006  which encourages pharmaceutical companies to invest in developing treatments for neglected diseases           We have the technology and brain power to bring about cures for these damaging diseases  but what   s lacking is a market incentive to tackle them     said Lieberman     This bill will help bring relief to thousands of people suffering from ancient diseases in a world with contemporary medical capabilities              In the developing world  millions of people suffer from curable diseases that many of us think no longer exist     said Senator Brownback      The biggest challenge to finding cures for these diseases is the lack of a market           Neglected diseases include HIV  TB and malaria but also leprosy  hookworm  and river blindness which themselves cause over 500 000 deaths annually   A total of 13 such diseases afflict the poor in Africa  Asia  and the Americas   Africa bears the brunt of them  as nearly 90 percent of the world   s neglected diseases afflict people in the continent        Lieberman continued     The technology and brain power behind cures should not be limited to the privileged and our bill aims to remove the barriers that have too long prevented these cures from reaching the nation   s underprivileged   The financial benefit companies would receive from the patent incentives in our bill can help offset the cost of crucial R investments needed to combat these neglected diseases  which can be as high as  1 billion dollars per drug           Brownback continued     The lack of interest in finding treatments for neglected diseases has led to only a few new drugs in the market  Between 1975 and 1997  only 13 new drugs were developed for neglected diseases   Because pharmaceuticals are expensive to develop  companies have fewer incentives to pursuer therapies when the purchases are primarily poor people   We can encourage pharmaceutical companies by granting a patent extension for a lifestyle drug or a neglected disease product if they make the investment to develop a treatment for a neglected disease   A drug company can recoup costs incurred by developing drugs for a neglected disease by securing these new patent rights           HIV  TB and malaria kill as many as 4  2  and 1 million people a year  respectively   Their victims often suffer from additional neglected diseases  which add to their suffering and hasten death        Lieberman  a leader in research and public health issues regarding infectious diseases  introduced the Project BioShield II Act of 2005 to address concerns about the many obstacles in the development of bioterrorism antidotes by private companies  including tax  intellectual property and liabilities risks that inhibit development  The BioShield law passed last year and modeled on provisions in the earlier Lieberman Hatch legislation authorizes  5 6 billion over 10 years for the government to procure drugs  biological products  and devices as countermeasures against biological  chemical  radiological and nuclear agents that could cause a public health threat         30                  